Precise regulation of FGF23 is required for bone health
Just the right amount of FGF23 is required to maintain healthy bone and mineral metabolism. FGF23 deficiency results in tumoral calcinosis, because loss of this factor impedes renal phosphate excretion and enables unopposed parathyroid hormone-dependent (PTH-dependent) stimulation of 1,25-dihydroxyvitamin D [1, 25(OH) 2 D] production, which together culminate in hyperphosphatemia and metastatic calcification (1) . In contrast, FGF23 overload results in hypophosphatemic rickets, which is characterized by inappropriately low levels of 1,25(OH) 2 D (2, 3). Yet, for all we have learned about FGF23 in the past decade, the fundamental mechanisms of how FGF23 overload leads to rickets is still unclear. Is the primary driver FGF23 excess, phosphate depletion, 1,25(OH) 2 D depletion, secondary calcium depletion, a combination of these, or other factors altogether?
Targeting CYP24A1 ameliorates skeletal abnormalities
In this issue, Bai et al. shed important new light on this controversy (4) . Specifically, the authors investigated the role of CYP24A1, the cytochromal enzyme that catalyzes the first step in vitamin D degradation, in the pathogenesis of two prototypical disorders of primary FGF23 excess: X-linked hypophosphatemic rickets (XLH), which is caused by mutations in PHEX that lead to elevated FGF23 through unknown mechanisms, and autosomal dominant hypophosphatemic rickets (ADHR), which results from activating mutations in FGF23 itself. Bai and colleagues crossed Hyp mice, which are the murine homolog of human XLH and FGF23 transgenic mice, which overexpress the cleavage-resistant form of FGF23 (FGF23 R176Q ) produced in human ADHR, with Cyp24a1-null mice. As a secondary approach to evaluate the involvement of CYP24A1 in these diseases, Hyp and ADHR mice were also treated with a pharmacological CYP24A1 inhibitor (4) .
Using this experimental approach, Bai and colleagues demonstrated that either genetic deletion or pharmacological inhibition of CYP24A1 induces near-complete healing of rickets in Hyp and ADHR mice. Amelioration of the animals' skeletal defects occurred in the absence of correcting severe hypophosphatemia or altering serum calcium levels. On the basis of these results, Bai et Overexpression of FGF23 results in hypophosphatemic rickets, which is characterized by renal phosphate wasting, inappropriately low circulating levels of the active form of vitamin D, and skeletal abnormalities. The precise mechanisms of how excess FGF23 leads to hypophosphatemic rickets are not clear. In this issue of the JCI, Bai and colleagues demonstrate that deletion or inhibition of CYP24A1, which initiates degradation of the active form of vitamin D, ameliorates skeletal abnormalities in two mouse models of hypophosphatemic rickets. While this work supports an important role for excess CYP24A1 activity in the pathogenesis of FGF23-mediated hypophosphatemic rickets, more work will need to be done before CYP24A1 inhibition can be integrated into the management of patients living with these diseases. jci. 
Conclusions and future directions
The current standard of care for XLH and ADHR includes the administration of oral 1,25(OH) 2 D and phosphate supplements; however, these treatments, which address downstream consequences of the diseases rather than the root causes, are only partially effective and often poorly tolerated (16, 17) . Novel strategies for these diseases are currently under development. For example, neutralizing antibodies against FGF23 directly target the underlying molecular mechanism of disease (18) , and FGF receptor antagonists inhibit the end-organ effects of FGF23 (19) . While the results of the current study by Bai and colleagues suggest that targeting CYP24A1 may be another viable therapeutic strategy, especially to correct the underlying skeletal defects, the inability to correct hypophosphatemia suggests that CYP24A1 antagonists may need to be relegated to an adjunctive role. Furthermore, the finding that circulating 1,25(OH) 2 D levels increased significantly in Hyp mice that were treated with the CYP24A1 inhibitor raises the question as to whether exogenous calcitriol treatment, which was not tested by Bai et al., could have achieved similar skeletal success. More in-depth research will be needed to define a new and improved standard of care for XLH, ADHR, and related conditions. Beyond those orphan diseases of primary FGF23 excess, could there be a role for CYP24A1 inhibition in diseases of secondary FGF23 excess, such as chronic kidney disease? If elevated FGF23 accelerates 1,25(OH) 2 D degradation by stimulating CYP24A1 in extra-renal tissues, as it appears to in bone, treating kidney disease lactone formation in Cyp24a1-KO mice (9) . Since 1α,25-(OH)2D3-26,23-lactone can act as a vitamin D receptor antagonist and thus inhibit osteoclastogenesis and bone resorption (10) , the extent to which rescue of the bone phenotype observed by Bai and colleagues can be explained entirely by the increase in the half-life of local 1,25(OH) 2 D or by an additional contribution of the concomitant absence of 1α,25-(OH)2D3-26, 23-lactone is not certain.
As Cyp24a1-null mice are unable to degrade 1,25(OH) 2 D, it is somewhat surprising that 1,25(OH) 2 D levels are low and hypercalcemia is absent in these animals. Indeed, approximately 50% of Cyp24a1-KO mice die in the early postnatal period due to endogenous 1,25(OH) 2 D intoxication and consequent hypercalcemia (11) . For reasons that are not clear, the other 50% are capable of lowering their circulating 1,25(OH) 2 D levels to the point that hypercalcemia can be avoided and prolonged survival is possible (11) . Thus, another important limitation of the study by Bai and colleagues is that only the progeny of Cyp24a1-KO mice that successfully adapted their vitamin D homeostasis to survive can be studied. Is it appropriate to proclaim skeletal success when only the hypercalcemia-resistant half of the progeny were analyzed? As a corollary, do the results understate the risks related to hypercalcemia in the event that all-comer human hypophosphatemic rickets patients are treated with CYP24A1 inhibitors?
In addition to highlighting the pathogenic role of excessive CYP24A1 activity in hypophosphatemic rickets, the study by Bai and colleagues emphasizes important differences between systemic and local regulation of vitamin D and the delicate balance between 1,25(OH) 2 D synthesis and degradation (Figure 1 ). The kidney is the primary source of the circulating pool of 1,25(OH) 2 D. Systemically, PTH is the primary factor that increases circulating 1,25(OH) 2 D levels by stimulating renal expression of CYP27B1, and FGF23 is the main inhibitor of renal 1,25(OH) 2 D production (12) . Locally, tissues can produce their own 1,25(OH) 2 D from 25(OH)D, as is well described in parathyroid chief cells, keratinocytes, and macrophages (13) . The observation by Bai and colleagues that systemic 1,25(OH) 2 D levels were low but the tissue effects were pronounced clearly
